An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Imvax Appoints John M. Limongelli as Chief Legal Officer
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
PHILADELPHIA--(BUSINESS WIRE)--
Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company’s Chief Legal Officer effective September 16, 2021.
“John’s breadth of experience in the biopharma industry, his deep technical acumen, and his expertise at helping build strong corporate practices will be of invaluable benefit to our leadership team,” said John Furey, Chief Executive Officer. “As we work to expand our platform to address a variety of solid tumors, John’s expertise will be an essential part of the development of these assets.”
Mr. Limongelli is an accomplished executive officer and lawyer with nearly 25 years of public company experience. Prior to Imvax, Mr. Limongelli served as Senior Vice President, General Counsel and Corporate Secretary at Neos Therapeutics, Inc., a publicly traded biotechnology company. He previously worked at Trevena, Inc. (NASDAQ: TRVN), where he was Senior Vice President, General Counsel and Chief Administrative Officer. Earlier in his career Mr. Limongelli held high-level legal roles at Cigna Corporation, Adolor Corporation, and Cephalon, Inc. He began his legal career in private practice with Morgan, Lewis & Bockius, LLP, and was a Certified Public Accountant with KPMG LLP. Mr. Limongelli obtained both his J.D. and MBA from Temple University.
“I’m excited to join the Imvax team in this time of rapid growth of the Company’s therapeutic portfolio,” said Mr. Limongelli. “Imvax’s unique immuno-oncology platform has shown enormous potential, and I am looking forward to working closely with the team to leverage this approach to deliver novel therapeutics for patients.”
About Imvax, Inc. Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com.
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
